Tiziana Reports Positive Longer-Term Data for Foralumab in MS Expanded Access Program

summarizeSummary

Tiziana Life Sciences reported updated positive clinical data for its intranasal foralumab in MS, showing encouraging trends in disability stabilization and fatigue improvement in an Expanded Access Program.

check_boxKey Events

• Updated Clinical Data for Foralumab

  Intranasal foralumab showed encouraging trends in stabilizing disability (EDSS) and improving fatigue (MFIS) in 14 patients with non-active Secondary Progressive Multiple Sclerosis over extended treatment durations.

• Favorable Safety Profile

  The drug continued to be extremely well tolerated with no new safety signals identified, supporting its long-term use.

• Data Limitations Noted

  The results are from a small sample size and are not statistically significant, representing trend analysis only.

• Context of Financial Health

  This positive clinical update follows a recent 'going concern' warning in the company's 20-F filing, making any positive development for its lead candidate particularly important for future financing prospects.

auto_awesomeAnalysis

Tiziana Life Sciences announced updated clinical data from its Expanded Access Program for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. The data, while from a small sample and not statistically significant, showed encouraging trends in stabilizing disability and improving fatigue over extended treatment durations, alongside a favorable safety profile. This positive clinical update provides further support for the drug's potential, which is crucial for the company given its recent 'going concern' warning.